Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07588945 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT

Name: daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT — clinical trial record (NCT07588945)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorInstitute of Hematology & Blood Diseases Hospital, China

Started2026-06-01

View on ClinicalTrials.gov ↗

Institute of Hematology & Blood Diseases Hospital, China

318 trials monitored

See 9 trials at risk

This study aims to evaluate the efficacy of prophylactic ruxolitinib in adult patients at intermediate-to-high risk of severe acute GvHD, as predicted by the daGOAT model.

Trial Details

NCT Number	NCT07588945
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Transplant-Related Disorder
Enrollment	438 participants
Start Date	2026-06-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-15